Common use of FDA Filings Clause in Contracts

FDA Filings. Introgen shall be responsible for the preparation and filing of all IND's in North America with respect to the Collaboration Products, which shall be filed in Introgen's name; provided RPRP shall have a reasonable opportunity to review and comment upon such filings in advance of their filing. RPRP shall be responsible for all further submissions to existing INDs once Later Stage Clinical Development has begun, provided that Introgen is given a reasonable opportunity to review and comment upon such submissions prior to the filing of such submissions. Introgen shall cooperate in transferring to RPRP authority for such correspondence. RPRP, at its expense, shall prepare all PLAs and ELA's for filing in North America with respect to each Collaboration Product. All such PLA's and ELA's shall be filed in the names of RPRP and Introgen, to the extent permitted by applicable FDA regulations (taking into account the supply arrangements under Section 12.3. below), or in such other manner as the Development Committee approves. In addition, RPRP shall in all events have the right to file separately a PLA/ELA in its own name to qualify, as a permitted supply source for the United States, its manufacturing facility for the RPRP Territory (consistent with Section 12.3. below).